Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brodalumab · 1 trial · 18 indications
The number of adverse events of each grade that occur and the number of adverse events attributed to brodalumab, as per the Common Terminology Criteria for Adverse Events version 5 (CTCAE v5).
The percentage of patients whose primary irAE severity decreased by \>1 grade per CTCAE criteria from study completion to treatment discontinuation.
| Arm | Type | Description |
|---|---|---|
| brodalumab to treat irAEs in patient with solid tumors | EXPERIMENTAL | Brodalumab 210 mg subcutaneous injection on weeks 0, 1, 2 followed by administration every 2 weeks until week 24 |
| Name | Type | Description |
|---|---|---|
| Brodalumab | DRUG | Brodalumab 210 mg subcutaneous injection |
| CT scan | RADIATION | CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment |
Inclusion Criteria: * Ability to provide written informed consent by subject or guardian * Individuals \>18 years of age * Diagnosis of an irAE clinically suspected to be IL-17 mediated * Intent-to-treat or prior treatment with systemic steroids for irAE management * Histology-proven primary advanc...
Top 20 of 92 competitors
Brodalumab is being studied for the treatment of immune-related adverse events in patients with breast cancer and other solid tumors. It is in Phase 1 clinical development as an investigational therapy. The drug is being evaluated in a single-arm, uncontrolled trial that is currently recruiting participants.
Brodalumab is a monoclonal antibody (mab) that targets the interleukin-17 receptor. By blocking this receptor, it is intended to modulate the immune response. In the context of the ongoing trial, it is being investigated for its potential to manage immune-related adverse events in cancer patients.
Brodalumab is being developed by Bausch + Lomb Corporation, which trades under the ticker symbol BLCO. The company is conducting a Phase 1 clinical trial of the drug for the treatment of immune-related adverse events in patients with various solid tumors, including breast cancer.
Brodalumab is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients and is designed to evaluate the drug's safety and efficacy in treating immune-related adverse events.
Brodalumab is being evaluated in a Phase 1 clinical trial with the identifier NCT06673329. The trial, titled 'Brodalumab in the Treatment of Immune-Related Adverse Events,' is recruiting participants in the United States. It is an uncontrolled, open-label study enrolling approximately 11 patients with various solid tumors.
Brodalumab is a distinct monoclonal antibody and is not known to be the same as other drugs. It is being investigated for its potential role in managing immune-related adverse events in oncology. The drug is in Phase 1 development and has not been approved for any indication.